1464910-32-4

JG26 is an ADAM17 inhibitor. JG26 also inhibits AngII-induced EGFR transactivation and ERK activation in cultured vascular smooth muscle cells (VSMCs).

JG26 is an ADAM17 inhibitor, with IC50 values of 12 nM, 1.9 nM, 150 nM and 9.4 nM for ADAM8, ADAM17, ADAM10 and MMP-12, respectively[1].

ADAM17: 1.9 nM (IC₅₀); MMP-12: 9.4 nM (IC₅₀); ADAM8: 12 nM (IC₅₀); ADAM10: 150 nM (IC₅₀); MMP-8: 240 nM (IC₅₀); MMP-9: 1630 nM (IC₅₀); MMP14: 19500 nM (IC₅₀); MMP-9: >500000 nM (IC₅₀)

[1] Doretta Cuffaro, et al. Discovery of Dimeric Arylsulfonamides as Potent ADAM8 Inhibitors. ACS Med Chem Lett. 2021 Oct 8;12(11):1787-1793. DOI:10.1021/acsmedchemlett.1c00411